|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of the +331G/A progesterone receptor gene (PgR) polymorphism with risk of endometrial cancer in Caucasian women: a meta-analysis.
|
25037596 |
2015 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Aberrant methylation patterns were observed in the first exon of PR gene, and the methylation density is correlated with the differentiation of different types of endometrial cancer cells.
|
17556066 |
2007 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings provide empirical evidence that PGR rs1042838 and rs10895068 polymorphisms may be involved in the pathogenesis of endometrial cancer.
|
26881523 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of 7 tag SNPs that were assessed, 2 polymorphisms in the 3' flanking region of the PGR gene, reference SNP identification number (rs) 11224561 (rs11224561) and rs471767, were associated with the risk of endometrial cancer.
|
19382201 |
2009 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the +331G/A hPR gene polymorphism may contribute to endometrial cancer risk by increasing expression of the hPR-B isoform.
|
12218173 |
2002 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status.
|
10101596 |
1999 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in LD block 3 of the PGR locus was associated with endometrial cancer risk (P(global test) = 0.002), with haplotypes 3C, 3D and 3F associated with 31-34% increased risk.
|
20547493 |
2010 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An application to progesterone-receptor haplotypes and endometrial cancer further illustrates that the performance of all these methods depends on how well the observed haplotypes "tag" the unobserved causal variant.
|
15637718 |
2005 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present case-control study is to evaluate the role of the PROGINS polymorphisms, as risk factor, for endometrial cancer development and to investigate the association between these genetics variants and clinical/pathologic variables of endometrial cancer.
|
17291258 |
2007 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also investigated whether the expression of estrogen receptors (ERalpha and ERbeta), progesterone receptor, and androgen receptor genes are influenced by the CYP1B1 genotypes in endometrial cancer.
|
12873984 |
2003 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The insulin-like growth factor (IGF) system is related to EC risk, and IGF-I can inhibit PR transcription in breast cancer.
|
21168492 |
2011 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have validated the endometrial cancer risk association with a tagSNP in the 3' untranslated region of PGR previously reported in an Asian population.
|
21148628 |
2011 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
181 genes were significantly up- or down-regulated with increasing BMI in endometrioid EC (q-value<0.01), including LPL, IRS-1, IGFBP4, IGFBP7 and the progesterone receptor.
|
27288544 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
One of the most prevalent potential therapeutic targets for women with endometrioid endometrial cancer (EC) is the estrogen receptor (ER)/progesterone receptor (PR) pathway.
|
30616900 |
2019 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The silencing of MIG6 using siRNA eliminated the P4-mediated reduction of EC cell viability, indicating that MIG6 is an essential downstream component of PR-mediated growth suppression.
|
28516379 |
2017 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated the estrogen-like effects of tamoxifen on the acceleration of growth and increased progesterone receptor concentrations of human endometrial carcinomas grown in the nude mouse experimental model.
|
1733196 |
1992 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NUCB2 immunoreactivity was detected in 19 out of 87 (22%) of endometrial carcinoma cases examined, and positively correlated with Ki67 labeling index, while there was no significant correlation between NUCB2 and stage, histological grade, and progesterone receptor status.
|
26842712 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this retrospective study was to explore the possible correlation in the EC microenvironment between master regulators of complex phenomena such as steroid responsiveness through estrogen receptor alpha (ERα) and progesterone receptor (PR), epithelial-to-mesenchymal transition (supported by SLUG transcription factor), hypoxia (with hypoxia inducible factor-1 alpha, HIF-1α), and obesity that has been recognized as a EC risk factor.
|
31220580 |
2019 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The prediction model using serum CA125 and the immunohistochemical markers PR and Ki67 is useful to predict patients with a low risk of LNM and has the potential to provide valuable guidance to clinicians in the treatment of patients with endometrioid endometrial cancer.
|
27163153 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the immunohistochemical expression of the estrogen receptor (ER) and progesterone receptor (PR), p14, p53, phosphatase and tensin homolog (PTEN), Ki67, in patients with endometrial hyperplasia (EH) with/without atypia versus endometrioid endometrial carcinoma type 1.
|
29250656 |
2017 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pathways including progesterone receptor, TGFβ, ETV5 and microRNAs are deeply related to the EMT process in EC.
|
22911547 |
2012 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of these studies was to reestablish high progesterone receptor isoform A and B gene expressions in such endometrial cancer cells and to examine the effects of progestin treatment on cell growth and metastatic potential after this transformation.
|
11303185 |
2001 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Only one (4.2%) of 24 endocervical carcinomas was positive for both estrogen receptor and progesterone receptor, whereas 18 (75%) of 24 endometrial carcinomas were positive for estrogen receptor and 23 (95.8%) of 24 endometrial carcinomas were positive for progesterone receptor (p <0.001, chi2 test).
|
12170086 |
2002 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of uteroglobin and matrix metalloproteinase-9 genes in endometrial cancer: relationship to estrogen and progesterone receptor status.
|
14719079 |
2004 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endometrial carcinomas and their metastases were generally positive for ER (86%), PR (93%) and VIM (100%) but rarely positive for CEA (14%) and HPV (0%).
|
15010819 |
2004 |